Cost-effectiveness of pembrolizumab for previously treated MSI-H/dMMR solid tumours in the UK

Patients with previously treated microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) tumours have limited chemotherapeutic treatment options. Pembrolizumab received approval from the EMA in 2022 for the treatment of colorectal, endometrial, gastric, small intestine, and biliary...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of medical economics 2024, Vol.27 (1), p.279-291
Hauptverfasser:	McCarthy, Grant, Young, Kate, Madin-Warburton, Matthew, Mantaian, Tyler, Brook, Elizabeth, Metcalfe, Kaylie, Mikelson, Jan, Xu, Ruifeng, Seyla-Hammer, Carl, Aguiar-Ibáñez, Raquel, Amonkar, Mayur
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal, Humanized Antineoplastic Agents, Immunological Bayes Theorem Brain Neoplasms Colorectal Neoplasms - drug therapy Cost-Benefit Analysis Humans Microsatellite Instability Neoplastic Syndromes, Hereditary United Kingdom
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!